Science
Mechanism of Action
This compound acts as a prodrug, undergoing intracellular metabolism primarily within dysplastic and highly proliferative skin cells to form protoporphyrin IX (PpIX). PpIX is a robust photosensitizing molecule. When PpIX-accumulated cells are exposed to light of an appropriate wavelength (e.g., blue or red light), the PpIX becomes photoactivated. This process instigates the production of cytotoxic reactive oxygen species and free radicals, leading to the targeted destruction of the abnormal cells.
Research
Clinical Evidence
High confidence10-20% (for PDT)
Key findings
- 01 Topical 10% aminolevulinic acid gel (Ameluz®) achieved an 83.4% clinical clearance rate for actinic keratosis when combined with red light.
- 02 A 10% aminolevulinic acid nanoemulsion gel (BF-200 ALA) is approved for topical photodynamic therapy (PDT) for actinic keratosis, enhancing epidermal penetration.
- 03 The application of 10% aminolevulinic acid (Ameluz®) for 2 hours with occlusion, followed by 630-nm light, significantly improved cheek elasticity and hydration in patients with actinic keratosis.
- 04 A 20% solution of 5-aminolevulinic acid, followed by blue light therapy, yielded a 72% complete response rate for actinic keratosis lesions on the head in phase III trials after re-treatment.
- 05 A 20% 5-ALA HCl gel is effectively employed in photodynamic therapy for superficial basal cell carcinoma.
Transparency
Dusting Analysis
Ethyl Aminolevulinate HCl is a powerful pharmaceutical prodrug with a highly specific mechanism requiring controlled light activation for therapeutic effect. Its use is limited to prescription-based photodynamic therapy due to significant photosensitization risks and the targeted nature of its action. Consequently, it is not suitable or safe for general cosmetic 'dusting' or uncontrolled application.
The Formula
Formulation
Stability
Aminolevulinic acid and its esters, including Ethyl Aminolevulinate HCl, exhibit limited stability at neutral pH (above 7). Optimal stability is observed in acidic solutions, particularly at pH 6 or lower, with robust stability maintained at pH 4. Degradation rates increase with higher concentrations. The ingredient is hygroscopic, requiring protection from moisture.
Synergies
- Light exposure (specific wavelengths like blue or red light) is an essential co-factor for its therapeutic activation.
Conflicts
- Direct sunlight or bright indoor light exposure post-application is strictly contraindicated due to severe photosensitization, requiring avoidance for a minimum of 48 hours.
- Combinations with other skincare products should only be pursued under the guidance of a healthcare professional due to potential interactions and heightened risks.
Safety
Safety Profile
Aminolevulinic acid (the parent compound) is an FDA-approved prescription drug for Photodynamic Therapy (PDT), indicated for medical treatments such as actinic keratoses, basal cell carcinoma, and Bowen's disease. Ethyl Aminolevulinate HCl has not undergone specific assessment by the Cosmetic Ingredient Review (CIR) or the Scientific Committee on Consumer Safety (SCCS) for cosmetic use. Under PDT, common side effects include tingling, stinging, burning, irritation, pain, redness, swelling, scaling, peeling, dryness, blistering, bleeding, or scabbing at the application site. The ingredient induces extreme skin photosensitivity, necessitating rigorous avoidance of direct sunlight or bright indoor light for at least 48 hours post-application, as conventional sunscreens do not provide adequate protection against this drug-induced sensitivity.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Due to its status as a prescription-only pharmaceutical requiring specific light activation for targeted medical therapies, coupled with high irritancy and severe photosensitization risks, Ethyl Aminolevulinate HCl is fundamentally unsuitable and unsafe for general cosmetic applications.
Related
Similar Ingredients
Finding similar ingredients…